If you have spent the last few months scrolling through injection options for stubborn heel pain, give yourself credit. People who research botulinum toxin (Botox) and dextrose prolotherapy for plantar fasciitis are usually the ones who have already done the patient, disciplined work — the calf stretching, the night routine, the shoe swaps — and are now looking for something with real clinical horsepower behind it. That instinct is sound. These are not fringe treatments. They are studied, injectable therapies that show up in the medical literature with genuine, measurable effects on heel pain.

And in 2026 we finally have the cleanest head-to-head comparison the field has ever produced. A network meta-analysis published in Scientific Reports pooled 63 randomized controlled trials and 4,170 participants (PROSPERO registration CRD420250641285) to rank the most common minimally invasive plantar fasciitis treatments against each other — shockwave therapy, prolotherapy, platelet-rich plasma, corticosteroids, and botulinum toxin A — across short-, mid-, and long-term follow-up. If you have been trying to figure out whether Botox or prolotherapy is the smarter bet, this is the study that finally puts numbers to the question.

So let's walk through exactly what it found. Then let's talk about the one variable the injection debate almost always leaves out — the mechanical load that put your fascia under strain in the first place, and why that variable decides whether any injection actually holds.

Botox: the fastest knockdown, but a short fuse

Botulinum toxin A came out of the 2026 analysis as the single best option for short-term pain relief. In the first six weeks after treatment, BTA ranked at the very top of the table (P-score 0.95) and produced the largest pain reduction versus placebo of any intervention studied (standardized mean difference 2.09). It was also the strongest performer for shrinking plantar fascia thickness early on — a proxy for calming the inflamed, thickened tissue at the heel. A separate 2024 meta-analysis put the average pain improvement at roughly 2.6 points on a 10-point visual analog scale, with no meaningful increase in side effects.

The mechanism explains both the speed and the ceiling. Botox blocks acetylcholine release at the neuromuscular junction, relaxing the calf complex and dropping tension through the plantar fascia. That tension relief lands fast. But the 2026 authors were direct about the catch: BTA's benefit "appears transient," and they observed no sustained superiority after roughly three months. It is, in their words, a short-term neuromodulatory option — not a durable fix. An earlier randomized trial comparing botulinum toxin against corticosteroid injection found Botox actually pulled ahead by the six-month mark, which tells you the relief is real — it just isn't permanent.

Prolotherapy: slower to arrive, longer to stay

Dextrose prolotherapy told the opposite story. It was not the fastest option out of the gate, but it climbed to the top of the rankings exactly where Botox faded. For mid-term pain relief (six to twelve weeks) prolotherapy ranked first (P-score 0.84), and for long-term relief (beyond twelve weeks) it ranked first again, more decisively (P-score 0.93) — outperforming corticosteroid injection by a clear margin in the pooled data. A focused 2026 meta-analysis of dextrose prolotherapy versus corticosteroid injection reached the same conclusion: prolotherapy trades early speed for more durable benefit.

The takeaway from the head-to-head is not that one injection "wins." It is that they solve different problems on different clocks. Botox is a fast knockdown with a short fuse. Prolotherapy is a slow build toward something more lasting. Corticosteroids, notably, led short-term function gains but did not dominate any long-term outcome — a reminder that the old default shot is no longer the obvious first move. The study's own framing says it plainly: treatment "should be tailored to symptom duration and therapeutic goals rather than defaulting to one intervention alone."

The variable the injection debate keeps skipping

Here is the line in that 4,170-patient analysis that almost everyone scrolls past. The authors describe these injections as therapies "selected when first-line treatment has failed." First-line, in their own words, means activity modification, stretching, NSAIDs, and foot orthoses. Every injection in that study sits downstream of load management. None of them were designed to replace it.

That matters because of what plantar fasciitis actually is. The plantar fascia is a thick band of connective tissue running from your heel to the base of your toes, and it behaves like a structural cable holding the arch. Pain shows up when that cable is repeatedly overloaded — every heel strike that lands without enough arch support pulls on the same insertion point at the heel, thousands of times a day. Botox quiets the nerve signaling. Prolotherapy stimulates the tissue to remodel. But neither one changes the load that strikes the fascia tomorrow morning. If the mechanical input doesn't change, the tissue you just treated goes right back under the same strain.

This is the gap. It is not a knock on injections — it is the reason injections relapse. An expensive, well-targeted shot is being asked to outrun a load it was never engineered to manage.

Why inserts are the foundation, not the competitor

It's tempting to read a ranking table and assume the goal is to find the one therapy that beats the others. But the smarter read of the 2026 data is architectural. Injections are interventions you layer on top of a managed mechanical base. Orthotic inserts are that base. They are the only item in the first-line column you carry with you into every step, every day, indefinitely — which is precisely the timeframe over which fascia overload accumulates.

The orthosis evidence is honest about its own scope, and that honesty is a feature. The landmark Landorf randomized trial of 135 plantar fasciitis patients found foot orthoses produced small short-term improvements in pain and function — and, importantly, that quality prefabricated inserts performed comparably to expensive custom-molded devices. Inserts are not marketed here as a miracle that out-punches a targeted injection in week one. They are the consistent, low-friction load management that determines whether the gains from any other treatment survive past the three-month mark where Botox, for example, fades.

Think of it as a sequence rather than a contest. If your pain is acute and you need a fast knockdown, the data points toward Botox. If you're chasing durable relief in a stubborn case, prolotherapy and PRP rank highest long term. But underneath either choice, the input that re-strains the fascia every morning has to change — or you're scheduling the next injection before this one wears off. For a fuller walk-through of how to sequence the injectable options against conservative care, our 2026 decision tree for stubborn plantar fasciitis maps the whole pathway step by step.

Where shockwave and PRP fit in the ranking

Botox and prolotherapy get the headlines, but the 2026 table is worth reading in full because two other options performed quietly well across the board. Extracorporeal shockwave therapy (ESWT) showed broad efficacy at essentially every timepoint and every outcome — never the single top rank, but consistently effective and entirely non-injectable, which makes it an attractive middle path for people uneasy about needles. Platelet-rich plasma (PRP) was the standout for the structural measures: it ranked highest for reducing plantar fascia thickness at mid- and long-term follow-up and significantly outperformed corticosteroid injection on that measure. In other words, PRP appears to do the most to remodel the tissue itself over time, which is a different goal than simply muting pain.

What none of these four therapies share is any effect on the daily mechanical input. ESWT delivers acoustic energy to provoke healing; PRP concentrates your own growth factors to drive tissue repair; Botox quiets nerve signaling; prolotherapy irritates the tissue into remodeling. Four distinct biological levers — and not one of them touches the load that lands on your heel at 7 a.m. tomorrow. That is the through-line of the entire ranking, and it is exactly why every one of these sits in the "second-line" column behind load management.

How to actually use this

Start with the cheapest, most reversible change that alters daily load: get the arch supported and the heel insertion offloaded in the shoes you already live in. Give that four to six weeks of consistent wear alongside a calf-and-fascia stretching routine. If pain is severe or you simply can't wait, that's a legitimate reason to discuss an injection with a clinician — and the 2026 rankings give you the vocabulary to ask the right question: am I optimizing for fast relief or for durable relief? Match the therapy to that answer.

But whatever you add on top, don't skip the foundation. The most decorated injection in the table still relapses if it's asked to fight the same mechanical load alone. A quality orthotic insert is the one piece of the plan that works on every step you take between appointments — which, over a year, is most of them.

Frequently asked questions

Is Botox or prolotherapy better for plantar fasciitis?
The 2026 network meta-analysis found botulinum toxin A best for short-term pain relief (top rank within six weeks) but with benefit that fades after about three months, while dextrose prolotherapy ranked highest for mid- and long-term pain relief. Botox is the faster knockdown; prolotherapy is the more durable option. Neither addresses the mechanical load on the fascia, which is why inserts are recommended alongside either.

Do I still need orthotic inserts if I get an injection?
Yes. The same study describes injections as treatments used when first-line care — including foot orthoses — hasn't resolved the problem. Injections calm pain or remodel tissue, but they don't change the load that strikes the heel each day. Inserts manage that load so treatment gains are less likely to relapse.

Are prefabricated inserts as good as custom orthotics?
For plantar fasciitis specifically, the landmark Landorf trial found quality prefabricated inserts performed comparably to custom-molded devices at a fraction of the cost. A well-engineered prefab insert is a reasonable first step for most people.

How long before an injection wears off?
In the pooled 2026 data, botulinum toxin A showed no sustained superiority beyond roughly three months. Prolotherapy and PRP held their advantage longer term — but durability of any treatment improves when the underlying mechanical overload is managed with consistent arch support.

---

Reviewed and approved by the WYATT MVMT Care Team
Backing every step with 35+ years of custom orthotic engineering. This article is educational and is not a substitute for individualized medical advice; talk to a licensed clinician before starting or stopping any treatment for heel pain.